Development and validation of a psoriasis treatment acceptability measure through group concept mapping.
Concept elicitation
GCM
Group concept mapping
Patient preference
Patient-reported
Psoriasis
Psychometric
TAQ
Treatment acceptability questionnaire
Journal
Health and quality of life outcomes
ISSN: 1477-7525
Titre abrégé: Health Qual Life Outcomes
Pays: England
ID NLM: 101153626
Informations de publication
Date de publication:
08 Aug 2023
08 Aug 2023
Historique:
received:
06
04
2023
accepted:
12
07
2023
medline:
10
8
2023
pubmed:
9
8
2023
entrez:
8
8
2023
Statut:
epublish
Résumé
Psoriasis is a common autoimmune dermatologic condition which has a pronounced negative impact on patient quality of life and disease burden. Currently, there are a number of treatments available for psoriasis, with differences in efficacy, mechanism of action, mode of administration, adverse effects, and tolerability. However, a reliable, validated patient-reported instrument to address patient expectations and of psoriasis treatment has not been developed. This project was undertaken with the aim of developing a fit-for-purpose self-reported instrument to inform patient expectations and preferences of psoriasis treatments. Two studies, both utilizing qualitative and quantitative methods, were conducted in patients within the entire spectrum of psoriasis severity. In Study 1, a group concept mapping (GCM) exercise was conducted with dermatologists and moderate-to-severe psoriasis patients to identify concepts important in the treatment of psoriasis. In Study 2, a preliminary Treatment Acceptability Questionnaire (TAQ) was developed using GCM-derived concepts from Studies 1 and 2, followed by cognitive debriefing (CD) telephone interviews of the preliminary TAQ. In Study 2, another GCM exercise was conducted with mild and newly diagnosed psoriasis patients. Psychometric analyses were performed on the TAQ to evaluate validity and reliability. The Study 1 GCM exercise generated 43 concepts from moderate-to-severe psoriasis patients (n = 20) and dermatologists (n = 10). In Study 2, 37 GCM concepts were generated from mild and newly diagnosed psoriasis patients (n = 20). From the 2 GCM exercises, 28 concepts were selected to form the preliminary TAQ; CD interviews indicated strong understanding and relevance of TAQ items among patients with disease ranging from mild to severe. The final TAQ consisted of 20 items; psychometric analysis demonstrated strong validity and reliability of the TAQ. The TAQ is a novel psychometrically validated patient-reported instrument to inform healthcare providers of patients' expectations of and preferences for treatment of their psoriasis and can help in shared decision making between patients and physicians.
Sections du résumé
BACKGROUND
BACKGROUND
Psoriasis is a common autoimmune dermatologic condition which has a pronounced negative impact on patient quality of life and disease burden. Currently, there are a number of treatments available for psoriasis, with differences in efficacy, mechanism of action, mode of administration, adverse effects, and tolerability. However, a reliable, validated patient-reported instrument to address patient expectations and of psoriasis treatment has not been developed. This project was undertaken with the aim of developing a fit-for-purpose self-reported instrument to inform patient expectations and preferences of psoriasis treatments.
METHODS
METHODS
Two studies, both utilizing qualitative and quantitative methods, were conducted in patients within the entire spectrum of psoriasis severity. In Study 1, a group concept mapping (GCM) exercise was conducted with dermatologists and moderate-to-severe psoriasis patients to identify concepts important in the treatment of psoriasis. In Study 2, a preliminary Treatment Acceptability Questionnaire (TAQ) was developed using GCM-derived concepts from Studies 1 and 2, followed by cognitive debriefing (CD) telephone interviews of the preliminary TAQ. In Study 2, another GCM exercise was conducted with mild and newly diagnosed psoriasis patients. Psychometric analyses were performed on the TAQ to evaluate validity and reliability.
RESULTS
RESULTS
The Study 1 GCM exercise generated 43 concepts from moderate-to-severe psoriasis patients (n = 20) and dermatologists (n = 10). In Study 2, 37 GCM concepts were generated from mild and newly diagnosed psoriasis patients (n = 20). From the 2 GCM exercises, 28 concepts were selected to form the preliminary TAQ; CD interviews indicated strong understanding and relevance of TAQ items among patients with disease ranging from mild to severe. The final TAQ consisted of 20 items; psychometric analysis demonstrated strong validity and reliability of the TAQ.
CONCLUSIONS
CONCLUSIONS
The TAQ is a novel psychometrically validated patient-reported instrument to inform healthcare providers of patients' expectations of and preferences for treatment of their psoriasis and can help in shared decision making between patients and physicians.
Identifiants
pubmed: 37553594
doi: 10.1186/s12955-023-02162-6
pii: 10.1186/s12955-023-02162-6
pmc: PMC10408213
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
83Subventions
Organisme : Celgene
ID : N/A
Organisme : Celgene
ID : N/A
Organisme : Celgene
ID : N/A
Organisme : Celgene
ID : N/A
Organisme : Celgene
ID : N/A
Organisme : Amgen
ID : N/A
Organisme : Amgen
ID : N/A
Organisme : Amgen
ID : N/A
Organisme : Amgen
ID : N/A
Organisme : Amgen
ID : N/A
Informations de copyright
© 2023. BioMed Central Ltd., part of Springer Nature.
Références
JAMA Dermatol. 2018 Dec 1;154(12):1417-1423
pubmed: 30422277
JAMA Dermatol. 2013 Oct;149(10):1180-5
pubmed: 23945732
Arch Phys Med Rehabil. 2018 Dec;99(12):2496-2503
pubmed: 29852151
Qual Life Res. 2014 Aug;23(6):1687-700
pubmed: 24390766
Arch Dermatol. 2010 Aug;146(8):891-5
pubmed: 20713823
Br J Dermatol. 1995 Feb;132(2):236-44
pubmed: 7888360
JAMA Dermatol. 2021 Aug 01;157(8):940-946
pubmed: 34190957
J Patient Rep Outcomes. 2017;1(1):9
pubmed: 29757313
Am Health Drug Benefits. 2016 Dec;9(9):504-513
pubmed: 28465778
J Dermatolog Treat. 2013 Aug;24(4):255-60
pubmed: 23249143
Am J Clin Dermatol. 2016 Feb;17(1):87-97
pubmed: 26718712
N Engl J Med. 2009 Jul 30;361(5):496-509
pubmed: 19641206
J Am Acad Dermatol. 2013 Jan;68(1):64-72
pubmed: 22846688
Dermatol Online J. 2016 Feb 17;22(2):
pubmed: 27267186
Qual Health Res. 2005 Dec;15(10):1392-410
pubmed: 16263919
Br J Dermatol. 2014 Mar;170(3):672-680
pubmed: 24266717
Dermatology. 2018;234(5-6):157-165
pubmed: 30121657
Patient Prefer Adherence. 2016 Aug 24;10:1609-21
pubmed: 27601886
Implement Sci. 2015 Aug 07;10:109
pubmed: 26249843
Dermatology. 2019;235(3):167-174
pubmed: 30928986
Br J Dermatol. 2015;172(5):1210-21
pubmed: 25677764
JAMA Ophthalmol. 2017 May 1;135(5):415-422
pubmed: 28418500
J Am Acad Dermatol. 2019 May;80(5):1445-1447.e4
pubmed: 30244059
Patient Prefer Adherence. 2021 May 12;15:975-987
pubmed: 34012257
Eval Program Plann. 2012 May;35(2):236-45
pubmed: 22221889
J Dermatolog Treat. 2008;19(1):5-21
pubmed: 18273720
Value Health. 2007 Nov-Dec;10 Suppl 2:S94-S105
pubmed: 17995479
Perit Dial Int. 2018 Jul-Aug;38(4):305-308
pubmed: 29987067
JAMA Dermatol. 2015 Jun;151(6):651-8
pubmed: 25565304
Int J Qual Health Care. 2005 Jun;17(3):187-91
pubmed: 15872026
Clin Interv Aging. 2006;1(4):415-23
pubmed: 18046918
Arch Dermatol Res. 2012 Aug;304(6):433-41
pubmed: 22722916
Expert Opin Drug Deliv. 2011 Nov;8(11):1521-9
pubmed: 21995544
Br J Dermatol. 2003 Aug;149(2):323-31
pubmed: 12932239
JAMA. 2010 Aug 25;304(8):903-4
pubmed: 20736477
PLoS One. 2012;7(12):e52935
pubmed: 23285231
J Investig Dermatol Symp Proc. 2004 Mar;9(2):136-9
pubmed: 15083780
Health Qual Life Outcomes. 2006 Jun 06;4:35
pubmed: 16756666
BMC Med Res Methodol. 2019 Jan 8;19(1):7
pubmed: 30621586